Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Concussion (Diagnosis), Concussion, Mild...
Phase NA
Enrollment 54
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Following adolescent concussion, poor sleep health is common and relates to the development of persisting post-concussion symptoms, and uninjured adolescents (independent of concussion) also commonly experience sleep insufficiency. Given the sparse guidance that exists for clinicians to provide evidence-based sleep health recommendations for adolescents with a concussion, the primary objectives of this prospective randomized clinical trial of adolescents with a recent concussion are to discover if a multidimensional and prescriptive sleep health intervention leads to: 1) faster symptom resolution time, better sleep quality, or longer sleep duration; and 2) improved sleep habits, mental health, or academic engagement, relative to standard-of-care post-concussion sleep health guidance. Findings from this research will provide the basis for more precise sleep health recommendations for adolescents who experience a concussion.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Sleep Intervention — The investigators will randomly assign participants (adolescents with concussion) to a personalized sleep schedule and sleep health recommendation, based on a meeting with an administrator after enrollment and randomization. They will undergo testing prior to the intervention, after the intervention (2 weeks after the initial visit, intervention length=2 weeks), and 6 weeks after intervention completion.

Primary Outcomes

  • Concussion symptom resolution time (Through study completion, an average of 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-10
Completion: 2027-06-15
Eligibility
Age: 10 Years and older
Sex: ALL
Volunteers: false
Enrollment: 54 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Denver
Principal Investigators:
  • David R Howell, PhD (PRINCIPAL_INVESTIGATOR) - University of Colorado Denver | Anschutz
Contact Information
Study Contact:
David R Howell, PhD
7207771502
David.Howell@CUAnschutz.edu
Katelyn Hurlburt, BS
7207771502
Katelyn.Hurlburt@CUAnschutz.edu
David R Howell, PhD
University of Colorado Denver
Interventions
  • Behavioral: Sleep Intervention — The investigators will randomly assign participants (adolescents with concussion) to a personalized sleep schedule and sleep health recommendation, based on a meeting with an administrator after enrollment and randomization. They will undergo testing prior to the intervention, after the intervention (2 weeks after the initial visit, intervention length=2 weeks), and 6 weeks after intervention completion.
Study Locations (1 sites)
University of Colorado Denver, Aurora, Colorado 80045 United States
Eligibility Criteria
Inclusion Criteria: * Participants will be symptomatic at the time of enrollment (Post-Concussion Symptom Inventory \[PCSI\] score ≥9) * Diagnosed with a concussion by a healthcare provider using the American Congress of Rehabilitation Medicine diagnostic criteria * 10-19 years of age (aligned with World Health Organization definition of 'adolescent') Exclusion Criteria: * History of treatment for pre-concussion sleep-related disorders
Conditions Localized Malignant Solid Neoplasm, Anal...
Phase NA
Enrollment 104
Locations 18 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Exercise intervention — Complete supervised TH aerobic and progressive resistance exercise sessions
  • Other: Telemedicine — Complete supervised TH aerobic and progressive resistance exercise sessions
  • Other: Aerobic Exercise Intervention — Complete unsupervised aerobic exercise
  • Other: Exercise Intervention — Receive stationary bike, workbook, gloves, and resistance bands
  • Procedure: Accelerometry — Wear accelerometer
  • Other: Questionnaire Administration — Ancillary studies
  • Other: Interview — Ancillary studies
  • Other: Electronic Health Record Review — Ancillary studies

Primary Outcomes

  • Percentage of completed exercise sessions (Feasibility) (Up to 6 months)
  • Intervention attrition rate (Feasibility) (Up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-11
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 104 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Jennifer Ligibel, MD (STUDY_CHAIR) - Alliance for Clinical Trials in Oncology
  • Kathryn Schmitz, MD (STUDY_CHAIR) - Alliance for Clinical Trials in Oncology
Contact Information
Study Contact:
Lilli Johnson
773-834-4091
cancercontrolprotocols@alliancenctn.org
Site Public Contact
877-642-4691
Kaiser Permanente Dublin
Jennifer M. Suga
Kaiser Permanente Dublin
Interventions
  • Other: Exercise intervention — Complete supervised TH aerobic and progressive resistance exercise sessions
  • Other: Telemedicine — Complete supervised TH aerobic and progressive resistance exercise sessions
  • Other: Aerobic Exercise Intervention — Complete unsupervised aerobic exercise
  • Other: Exercise Intervention — Receive stationary bike, workbook, gloves, and resistance bands
  • Procedure: Accelerometry — Wear accelerometer
Study Locations (18 sites)
Kaiser Permanente Dublin, Dublin, California 94568 United States
Kaiser Permanente-Fremont, Fremont, California 94538 United States
Kaiser Permanente Fresno Orchard Plaza, Fresno, California 93720 United States
Kaiser Permanente-Modesto, Modesto, California 95356 United States
Kaiser Permanente-Oakland, Oakland, California 94611 United States
Kaiser Permanente-South Sacramento, Sacramento, California 95823 United States
Kaiser Permanente-Santa Teresa-San Jose, San Jose, California 95119 United States
Kaiser San Rafael-Gallinas, San Rafael, California 94903 United States
Kaiser Permanente-Vallejo, Vallejo, California 94589 United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
Eligibility Criteria
Inclusion Criteria: * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed diagnosis of one of the following cancers: anus, bladder, breast, cervix, colon/rectum, endometrium, esophagus, gallbladder, head/neck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, stomach * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting are eligible. Patients receiving definitive chemoradiation for the tumors listed above, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have metastatic cancer * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of current alcohol, substance abuse, or dementia * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Engaged in full time gainful employment of at least 30 hours per week at the time of cancer diagnosis * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Currently no self-report of engagement in competitive sports (e.g. not training for running races, triathlons, etc.) AND no self-report of twice weekly progressive resistance exercise training for at least 3 consecutive months within the past year * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Self-reported ability to walk for 6 minutes (use of assistive devices will be allowed) * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not participating in another weight loss, physical activity, or dietary intervention clinical trial * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Predicted 6MWT distance of 550 meters or less * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Concurrent enrollment in treatment or supportive care trials (other than those focused on weight loss or exercise) is allowed with the permission of the Alliance Executive Officer and both studies' study chairs * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): The trial is unable to accommodate the needs of deaf or blind participants as the study relies on language and visualization of exercise through telehealth sessions * CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Clinicians and research staff from enrolling sites who meet following criterion will be deemed eligible to participate as a clinical stakeholder: \* Providing clinical care for participating patients on this study * CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Ability to speak and understand English Exclusion Criteria: \-
Conditions Mental Health Issue, Depression, Anxiety
Phase NA
Enrollment 204
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the usability, feasibility, and acceptability of a novel multi-level Just-In-Time Training (JITT) implementation strategy (JITT-EBP) that aims to equip mentors and mentor supervisors to implement evidence-based practices (EBPs) with fidelity using methods that are sustainable in rural communities. JITT-EBP integrates (a) self-directed, on-demand, online training modules for mentors and mentor supervisors, (b) synchronous evidence-based supervision strategies, and (c) an apprenticeship delivery model in which EBPs are co-led by an experienced mentor and a novice mentor, providing opportunity for in-the-moment training and support. The study will conduct a pilot hybrid type 2 effectiveness-implementation trial to evaluate the use of JITT-EBP compared to usual training for implementing mentor-delivered Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST), an evidence-based depression prevention program. 96 adolescents (age 12-17) and their parents, 8-18 mentors (depending on amount of turnover), and 4 mentor supervisors will be enrolled in the trial.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Interpersonal Psychotherapy-Adolescent Skills Training via Just-In-Time Training (JITT) implementation strategy — IPT-AST is a group-based EBP that aims to prevent depression and support emotional well-being by helping youth develop skills to foster healthy relationships. Youth learn about the links between feelings and interpersonal interactions, and they learn communication strategies and interpersonal problem-solving skills that they can apply to their relationships. JITT-EBP integrates (a) self-directed, on-demand, online training modules for mentors and mentor supervisors, (b) synchronous evidence-based supervision strategies, and (c) an apprenticeship delivery model in which EBPs are co-led by an experienced mentor and a novice mentor, providing opportunity for in-the-moment training and support.
  • Behavioral: Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST) implemented via usual training — IPT-AST is a group-based EBP that aims to prevent depression and support emotional well-being by helping youth develop skills to foster healthy relationships. Youth learn about the links between feelings and interpersonal interactions, and they learn communication strategies and interpersonal problem-solving skills that they can apply to their relationships. Usual training involves (a) a one-day virtual training conducted by an IPT-AST expert prior to the beginning of the intervention, and (b) synchronous evidence-based supervision strategies.

Primary Outcomes

  • Feasibility of Intervention Measure (FIM) - Week 12 (Week 12)
  • Acceptability of Intervention Measure (AIM) - Week 12 (Week 12)
  • Intervention Appropriateness Measure (IAM) - Week 12 (Week 12)
  • Client Satisfaction Questionnaire (CSQ-8) - Week 12 (Week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-18
Completion: 2028-05-31
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: true
Enrollment: 204 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Minnesota
Principal Investigators:
  • Meredith Gunlicks-Stoessel, PhD, LP (PRINCIPAL_INVESTIGATOR) - University of Minnesota
  • Lindsey Weiler, PhD (PRINCIPAL_INVESTIGATOR) - University of Minnesota
Contact Information
Study Contact:
Gracie Meyer
612-625-7240
meye3329@umn.edu
Gracie Meyer
612-625-7240
meye3329@umn.edu
University of Minnesota
Interventions
  • Behavioral: Interpersonal Psychotherapy-Adolescent Skills Training via Just-In-Time Training (JITT) implementation strategy — IPT-AST is a group-based EBP that aims to prevent depression and support emotional well-being by helping youth develop skills to foster healthy relationships. Youth learn about the links between feelings and interpersonal interactions, and they learn communication strategies and interpersonal problem-solving skills that they can apply to their relationships. JITT-EBP integrates (a) self-directed, on-demand, online training modules for mentors and mentor supervisors, (b) synchronous evidence-based supervision strategies, and (c) an apprenticeship delivery model in which EBPs are co-led by an experienced mentor and a novice mentor, providing opportunity for in-the-moment training and support.
  • Behavioral: Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST) implemented via usual training — IPT-AST is a group-based EBP that aims to prevent depression and support emotional well-being by helping youth develop skills to foster healthy relationships. Youth learn about the links between feelings and interpersonal interactions, and they learn communication strategies and interpersonal problem-solving skills that they can apply to their relationships. Usual training involves (a) a one-day virtual training conducted by an IPT-AST expert prior to the beginning of the intervention, and (b) synchronous evidence-based supervision strategies.
Study Locations (1 sites)
University of Minnesota, Minneapolis, Minnesota 55455 United States
Eligibility Criteria
Youth and Parent Inclusion Criteria: * student at a partnering rural middle school or high school * age 12-17 * have English speaking/reading/writing ability at a level to participate in IPT-AST * youth's parent has English or Spanish-speaking/reading/writing ability at a level to participate in research activities. Youth and Parent Exclusion Criteria: * moderate or severe depression (PHQ-9 \> 10) * active suicidal ideation with a plan and/or intent, requiring higher level of care * Youth does not have English-speaking ability at a level to participate in IPT-AST * youth's parent does not have English or Spanish-speaking/reading/writing ability at a level to participate in research activities. Mentor and Mentor Supervisor Inclusion Criteria: * age 18 or older * have completed the typical mentor or mentor supervisor screening and selection process at partnering mentoring organization (including a background check) * are available to facilitate the program during after-school hours.
Conditions Cataract, Hypertension
Phase PHASE3
Enrollment 126
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cataract surgery in elderly patients with controlled hypertension carries a risk of hemodynamic instability, particularly fluctuations in mean arterial blood pressure (MAP). Dexmedetomidine, a selective α2-adrenergic agonist, offers hemodynamic stabilization and sedation when administered intranasally and provides a simple and non-invasive premedication option. This study evaluates the effects of intranasal dexmedetomidine on perioperative mean arterial blood pressure in patients undergoing cataract surgeries. Research Question: Does intranasal dexmedetomidine premedication control blood pressure in elderly hypertensive patients undergoing cataract surgery? Research Hypothesis: Intranasal dexmedetomidine significantly reduces MAP and improves secondary outcomes compared to placebo. Primary Objective: To evaluate the efficacy of intranasal Dexmedetomidine as a premedication to control hypertension in elderly patients scheduled for cataract surgery. Secondary Objectives: 1. To assess surgery cancellation rates. 2. To evaluate satisfaction levels among patients, anesthesiologists, and surgeons using the Modified Observer's assessment of alertness/sedation scale (MOAA/S). 3- To evaluate the effect of intranasal dexmedetomidine on HR multiple readings starting from preoperative hold area till 2 hours postoperatively. This randomized, double-blinded clinical trial will include 126 elderly hypertensive patients (≥65 years) undergoing cataract surgery under local anesthesia. Inclusion Criteria will consist of patients aged ≥65 years, ASA II or III, stage 2 hypertension as per ACC / AHA guidelines (SBP\>140 and DBP\> 90 mmHg), undergoing elective cataract surgery under local anesthesia. Exclusion Criteria will include allergy or contraindication to dexmedetomidine, significant baseline bradycardia (\<50 bpm) or arrhythmia, use of sedative or anxiolytic medications, history of severe hepatic, renal, or cerebrovascular disease. Participants will be randomly assigned to receive either intranasal dexmedetomidine (1 mcg/kg ideal body weight) or a placebo (normal saline) 30 minutes before surgery. MAP, HR, and SpO₂ will be recorded at multiple perioperative intervals, and surgical cancellation rates, satisfaction levels will be noted, surgical duration, and hospital stay will be documented.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Intranasal dexmedetomidine — Intranasal dexmedetomidine (1 mcg/kg ideal body weight) will be diluted to a total volume of 1 ml and will be administered via a mucosal atomization device (MAD) 30 minutes before surgery. The dose will be divided evenly, with 0.5 mL sprayed into each nostril while the patient is in a semi-recumbent position.
  • Drug: Intranasal normal saline — Intranasal normal saline (1 ml) will be administered via mucosal atomization device (MAD) 30 minutes before surgery. The dose will be divided evenly, with 0.5 mL sprayed into each nostril while the patient is in a semi-recumbent position.

Primary Outcomes

  • Mean arterial blood pressure (MAP) (From preoperative baseline until 2 hours postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-07-16
Completion: 2026-05
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 126 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Suez Canal University
Contact Information
Study Contact:
Mohammad E Salama, MD
+201016865861
MohammadElhossieny88@med.suez.edu.eg
Abdelrhman M Alshawadfy, MD
+201091091620
abdelrhmanalshawadfy@gmail.com
Mahammad E Salama, MD
01016865861
mohammadelhossieny88@med.suez.edu.eg
Suez Canal University Hospitals
Interventions
  • Drug: Intranasal dexmedetomidine — Intranasal dexmedetomidine (1 mcg/kg ideal body weight) will be diluted to a total volume of 1 ml and will be administered via a mucosal atomization device (MAD) 30 minutes before surgery. The dose will be divided evenly, with 0.5 mL sprayed into each nostril while the patient is in a semi-recumbent position.
  • Drug: Intranasal normal saline — Intranasal normal saline (1 ml) will be administered via mucosal atomization device (MAD) 30 minutes before surgery. The dose will be divided evenly, with 0.5 mL sprayed into each nostril while the patient is in a semi-recumbent position.
Study Locations (1 sites)
Suez Canal University Hospitals, Ismailia, Ismailia Governorate 41522 Egypt
Eligibility Criteria
Inclusion Criteria: 1. Patients aged ≥65 years. 2. Patients who will have stage 2 hypertension as per ACC/AHA guidelines (Systolic BP \> 140 and Diastolic BP\> 90 mmHg) 3. Elective cataract surgery under local anesthesia. 4. American Society of Anesthesiologists (ASA) physical status II or III. Exclusion Criteria: 1. Allergy or contraindication to dexmedetomidine. 2. Significant baseline bradycardia (\<50 bpm) or arrhythmias. 3. Use of sedative or anxiolytic medications. 4. History of severe hepatic, renal, or cerebrovascular diseases.
Conditions Anatomic Stage 0 Breast Cancer AJCC v8, ...
Phase PHASE2
Enrollment 38
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial tests how well a probiotic, WBF-038, works in preventing bone loss in patients with early-stage hormone receptor-positive breast cancer who are starting treatment with aromatase inhibitors. Aromatase inhibitors are a drug that blocks the activity of an enzyme called aromatase, which the body uses to make estrogen in the ovaries and other tissues. Blocking aromatase lowers the amount of estrogen made by the body, which may stop the growth of cancer cells that need estrogen to grow. Aromatase inhibitors are used to treat some types of breast cancer or to keep it from coming back. Aromatase inhibitors can affect bone health, weight, blood sugar, and waist size. WBF-038 is a combination of both prebiotics and probiotics, designed to improve metabolic health. Giving WBF-038 may improve bone turnover, bone health, blood sugar, weight, and waist circumference in patients with early-stage hormone receptor-positive breast cancer starting on adjuvant endocrine therapy with an aromatase inhibitor.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Bone Mineral Density Test — Undergo BMD
  • Other: Questionnaire Administration — Ancillary studies
  • Drug: WBF-038 — Given WBF-038 PO

Primary Outcomes

  • Change in C-terminal telopeptide of type 1 collagen (CTx) (Baseline; 90 days after start of AI therapy (before beginning WBF-038); 14 days after start of WBF-038; 90 days after start of WBF-038; 180 days after start of WBF-038; 365 days after start of WBF-038; 90 days after stopping WBF-038)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-25
Completion: 2027-07-25
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 38 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Saranya Chumsri, MD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Mayo Clinic in Florida
Saranya Chumsri, MD
Mayo Clinic in Florida
Interventions
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Bone Mineral Density Test — Undergo BMD
  • Other: Questionnaire Administration — Ancillary studies
  • Drug: WBF-038 — Given WBF-038 PO
Study Locations (1 sites)
Mayo Clinic in Florida, Jacksonville, Florida 32224-9980 United States
Eligibility Criteria
Inclusion Criteria: * Female age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 * Histologically confirmed anatomical stage 0-III hormone receptor-positive breast cancer * Will be starting on an aromatase inhibitor (letrozole, anastrozole, or exemestane) ± ovarian function suppression (OFS) per treating physician's discretion * Absolute neutrophil count (ANC) ≥ 1000/mm\^3 (prior to registration) * Platelet count ≥ 75,000/mm\^3 (prior to registration) * Hemoglobin ≥ 9.0 g/dL (prior to registration) * Creatinine ≤ 2 x upper limit of normal (ULN) (prior to registration) * Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) ≤ 2 x ULN (prior to registration) * Albumin ≥ 3 g/dL (prior to registration) * Willing and able to provide research stool and blood samples * Negative serum pregnancy test done ≤ 7 days prior to registration, for women of childbearing potential only (\< 60 years old with intact uterus) * Capable of providing valid informed consent * Willing to return to enrolling institution for all study visits (blood draws, etc) Exclusion Criteria: * Requires prolonged systemic antibiotic therapy for other conditions and recent systemic antibiotic ≤ 14 days prior to registration * Fecal microbiota transplant (FMT) ≤ 6 months prior to registration * FMT with an associated serious adverse event related to the FMT product or procedure * Co-morbid systemic illnesses or other severe concurrent diseases which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of over-the-counter probiotics * Immunocompromised patients including patients known to be HIV positive or those on chronic steroids \> 20 mg prednisone a day or prednisone-equivalent. Note: Must be off systemic steroids ≥ 90 days prior to registration. However, topical steroids, inhalants, or steroid eye drops are permitted * History of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's disease, or microscopic colitis * History of chronic diarrhea * History of celiac disease * Currently has a colostomy * Intraabdominal surgery related to gastrointestinal tract ≤ 60 days prior to registration * Evidence of active, severe colitis * History of short gut syndrome or motility disorders * Requires the daily use of medications to manage bowel hypermotility, such as imodium or lomotil * Active autoimmune disease that has required systemic treatment in the ≤ 30 days (i.e., with the use of disease-modifying agents, corticosteroids, or immunosuppressive products) prior to registration. Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. Patients with vitiligo, Graves' disease, or psoriasis not requiring systemic treatment ≤ 30 days prior to registration are not excluded * History of osteoporosis or hyperparathyroidism * History of untreated vitamin D deficiency * Receiving or will receive bisphosphonates during study period (alendronate, risedronate, ibandronate, pamidronate, or zolendronic acid) or denosumab * Patients who received oral bisphosphonate within ≤ 12 weeks, intravenous (IV) zoledronic acid (Reclast) ≤ 52 weeks, or denosumab ≤ 24 weeks will also be excluded * Known hypersensitivity to any component of study product (including known inulin intolerance) * Known hypersensitivity to \> 4 first-line antimicrobial therapies against akkermansia muciniphila, clostridium beijerinckii, clostridium butyricum, anaerobutyricum hallii, including penicillin, piperacillin, tetracycline, amoxicillin, or ampicillin * Known hypersensitivity to \> 4 first line antimicrobial therapies against bifidobacterium infantis Bi-26TM, including gentamicin, kanamycin, streptomycin, tetracycline, erythromycin, clindamycin, ampicillin, vancomycin * Received an experimental product ≤ 30 days prior to registration * Receiving or will receive CDK 4/6 inhibitor (abemaciclib, ribociclib, or palbociclib) * Received chemotherapy ≤ 30 days prior to registration
Conditions Preeclampsia, Gestational Hypertension
Phase PHASE2
Enrollment 204
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy. In addition, women with overweight/obesity are at increased risk for progression to chronic hypertension after experiencing hypertensive disorders of pregnancy. Among women with hypertensive disorders of pregnancy and pre-pregnancy overweight/obesity, the investigators will conduct a randomized trial to test the effect of pharmacologically blocking the mineralocorticoid receptor for three months after delivery on blood pressure and cardiac remodeling at nine months postpartum.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: spironolactone 25 mg orally once daily — Participants with hypertensive disorders of pregnancy will receive 25mg capsules of spironolactone to self-administer daily over the 12-week duration of the study treatment.
  • Drug: Placebo tablet to match spironolactone — Participants with Hypertensive disorders of pregnancy will receive placebo equivalent capsules to self-administer daily over the 12-week duration of the study treatment.

Primary Outcomes

  • Mean 24-hour ambulatory diastolic blood pressure (36 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-10-16
Completion: 2029-03-02
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 204 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: Brigham and Women's Hospital, University of Pittsburgh Medical Center
Contact Information
Study Contact:
Michael C Honigberg, MD, MPP
617-726-1843
mhonigberg@mgh.harvard.edu
Victoria R Viscosi, MS
617-724-2996
vviscosi@mgh.harvard.edu
Massachusetts General Hospital
Michael C Honigberg, MD, MPP
Massachusetts General Hospital
Interventions
  • Drug: spironolactone 25 mg orally once daily — Participants with hypertensive disorders of pregnancy will receive 25mg capsules of spironolactone to self-administer daily over the 12-week duration of the study treatment.
  • Drug: Placebo tablet to match spironolactone — Participants with Hypertensive disorders of pregnancy will receive placebo equivalent capsules to self-administer daily over the 12-week duration of the study treatment.
Study Locations (3 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
University of Pittsburgh Magee-Womens Hospital, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: * Females aged ≥18 years * HDP (gestational hypertension or preeclampsia) without pre-pregnancy chronic hypertension * BMI ≥25 kg/m2 prior to pregnancy or in the first trimester * Requirement for antihypertensive medication within one week of delivery * Ability to provide informed consent Exclusion Criteria: * LV ejection fraction \<50% or history of clinical heart failure with reduced or preserved ejection fraction * Hypertrophic or other genetic cardiomyopathy * Hyperkalemia: potassium \>5.3 mEq/L * BMI at screening ≥50 kg/m2 * Pre-pregnancy diabetes * Estimated glomerular filtration rate (eGFR) \<60mL/min/1.73 m2 * Cirrhosis * Primary aldosteronism * Intention to become pregnant within 9 months * Active substance abuse * Other serious medical illnesses or concerns about protocol adherence/ mortality within 9 months * Participation in another interventional clinical study * Hypersensitivity to spironolactone * Addison's disease * Concomitant use of eplerenone or finerenone
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 900
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to develop, implement, and evaluate a patient-centered triage and referral model designed to improve health outcomes for individuals with uncontrolled type 2 diabetes mellitus (T2DM) and unmet health-related social needs. The intervention builds on the existing THRIVE infrastructure at Boston Medical Center (BMC), which includes screening for social needs and a resource referral guide. It integrates medical and social care by embedding a data-driven triage tool within the EPIC electronic health record system, engaging community health workers trained in population health, and initiating closed-loop EPIC integrated referrals to community-based organizations. This study will use a hybrid type 3 effectiveness-implementation trial design to evaluate the implementation of the THRIVE-DM intervention at the clinic level. Preliminary effectiveness will be assessed by comparing THRIVE-DM to usual care in its ability to increase patient connections to community-based organizations and improve clinical outcomes. Using a stratified randomization approach, the investigators will compare referral closure rates, receipt of social services, hemoglobin A1C levels, and patterns of health service utilization between patients enrolled in THRIVE-DM and those receiving standard care

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: THRIVE-DM — Low-SS and High-SS will be referred by the CHW to appropriate community-based organizations through the THRIVE Directory. High-SS participants will also receive additional support from a patient navigator (PN), who will follow up to facilitate service connection and address barriers to engagement. CHWs and PNs will coordinate care to ensure services are aligned with the patient's assessed needs.
  • Other: Standard of care — Standard of care may include support from the primary care team, health related social needs (HRSN) screening via the THRIVE screener, printed resource guides, and referrals to community-based organizations initiated at the discretion of clinic staff using the THRIVE Directory.

Primary Outcomes

  • Number of participants that connect to Community-Based Organizations (3 months, 6 months, 3 months post intervention)
  • Number of participants that are helped by Community-Based Organizations (3 months, 6 months, 12 months post intervention)
  • Changes in HbA1c (3 months, 6 months, 12 months post intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-26
Completion: 2027-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 900 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Boston Medical Center
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Michael Fischer, MD (PRINCIPAL_INVESTIGATOR) - Boston Medical Center, Internal Medicine
Contact Information
Study Contact:
Michael Fischer, MD
617-414-7288
Michael.Fischer@bmc.org
Uma Khemraj, MS
617-414-7288
Uma.Khemraj@bmc.org
Micheal Fischer, MD
617-414-7288
Michael.Fischer@bmc.org
Boston Medical Center
Interventions
  • Other: THRIVE-DM — Low-SS and High-SS will be referred by the CHW to appropriate community-based organizations through the THRIVE Directory. High-SS participants will also receive additional support from a patient navigator (PN), who will follow up to facilitate service connection and address barriers to engagement. CHWs and PNs will coordinate care to ensure services are aligned with the patient's assessed needs.
  • Other: Standard of care — Standard of care may include support from the primary care team, health related social needs (HRSN) screening via the THRIVE screener, printed resource guides, and referrals to community-based organizations initiated at the discretion of clinic staff using the THRIVE Directory.
Study Locations (1 sites)
Boston Medical Center, Boston, Massachusetts 02118 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis: Must have a diagnosis of Type 2 Diabetes Mellitus (T2DM), confirmed by a current diagnosis in the medical record or at least two billing codes in the last two years, or an HbA1c level ≥6.5% in the last two years. * Uncontrolled T2DM: Must have an HbA1c ≥9% at the time of screening. * Health-Related Social Needs: Must have been screened for health related social needs (HRSNs) during a General Internal Medicine (GIM) visit in the last 3 months and screened positive for at least one HRSN. Exclusion Criteria: * Patients enrolled in Complex Care Management (CCM). * Patients receiving hospice care. * Patients who are deceased * Patients with Type 1 Diabetes Mellitus (T1DM).
Conditions Breast Cancer
Phase NA
Enrollment 70
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines. It has been suggested that sodium-glucose transporter-2 (SGLT2) inhibitors may reduce the damage to the heart caused by anthracycline chemotherapy. The investigators wish to determine whether dapagliflozin (SGLT2 inhibitor) taken daily during chemotherapy will reduce the rate of cardiotoxicity.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Drug: Sodium-glucose transport-2 (SGLT-2) inhibitors — Dapagliflozin 10mg in addition to standard clinical care
  • Other: Standard medical treatment — Standard clinical care

Primary Outcomes

  • Cardiac energetics (From enrolment to the end of treatment at the end of approximately 22 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-12
Completion: 2028-10-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Aberdeen
Collaborators: NHS Grampian
Principal Investigators:
  • Dana Dawson, MPhil (PRINCIPAL_INVESTIGATOR) - University of Aberdeen
Contact Information
Study Contact:
Sylvia Kamya, MBChB
+441224559573
sylvia.kamya@nhs.scot
Amelia Rudd, PhD
+441224559573
a.e.rudd@abdn.ac.uk
Dana Dawson, PhD
01224 437969
dana.dawson@abdn.ac.uk
Cardiac Research Office, Aberdeen Royal Infirmary
Interventions
  • Drug: Sodium-glucose transport-2 (SGLT-2) inhibitors — Dapagliflozin 10mg in addition to standard clinical care
  • Other: Standard medical treatment — Standard clinical care
Study Locations (2 sites)
Cardiac Research Office, Aberdeen Royal Infirmary, Aberdeen, Aberdeenshire AB25 2ZD United Kingdom
University of Aberdeen, Aberdeen, AB25 2ZD United Kingdom
Eligibility Criteria
Inclusion Criteria: * Patients with breast cancer between 18-70 years of age. * Patients with low to medium cardiovascular risk. * Patients scheduled for adjuvant or neo-adjuvant anthracycline therapy. * Patients who are able to give written informed consent to take part in the study. * Patients who can read and understand English. The current thresholds for defining cardiovascular risk for patients undergoing anthracycline chemotherapy are as follows: normal resting 12-lead electrocardiogram, plasma cardiac troponin I concentration \< 99th centile, serum brain natriuretic peptide concentration \<35 pg/mL or serum N-terminal pro-brain natriuretic peptide concentration \<125 pg/mL, left ventricular ejection fraction \>55%, global longitudinal strain \>-18% and healthy life-style (normal body-mass index, non-smoker). Low cardiovascular risk will allow for the presence of one abnormal life-style factor (body-mass index indicating obesity (\>30 kg/m2), current smoker or significant smoking history), or presence of only one of the following in the clinical history: hypertension, stage 1-2 chronic kidney disease, age 65-79 years, borderline left ventricular ejection fraction (50-54%) or elevated cardiac biomarkers. Medium cardiovascular risk will permit the combination of any 2-4 of the lifestyle or clinical history variables indicated above. Exclusion Criteria: * Patients with a known intolerance of dapagliflozin * Patients with high cardiovascular risk as specified by the most recent cardio-oncology guidelines. * Patients with significant renal impairment (estimated glomerular filtration rate \<45 mL/min/1.73 m2). * Patients with a previous cancer diagnosis. * Patients with known type 1 or 2 diabetes mellitus. We will not actively screen for diabetes. This is not done in clinical practice and there have been no issues. * Patients with a contraindication to magnetic resonance imaging. * Patients with prior exposure to anthracyclines. * Patients who cannot read and understand English. * Patients who are pregnant
Conditions Breast Cancer
Phase NA
Enrollment 1508
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer remains the most common cancer among women and a major cause of death despite advances in screening and treatment. Current screening programs are not personalized and are experiencing declining participation. A promising strategy for breast cancer control would be to implement risk-based prevention and early screening, targeting individuals at high risk of developing breast cancer, in order to improve chances of cure and reduce the need for more intensive treatments. The MyPeBS study was designed to assess whether personalized breast cancer screening (based on an individual's risk of developing breast cancer) is as effective as, or more effective than, current standard screening. Lifestyle interventions involving changes in diet or physical activity, for example, have been shown to be effective in reducing the risk of developing breast cancer, whether low or high. The MyPeBS study evaluates personalized screening but offers limited information on breast cancer prevention. MyPREV is a project that aims to assess the feasibility and impact of a personalized online program on breast cancer risk reduction measures. This program is offered to women at high risk of developing breast cancer as part of the European MyPeBS screening study. The main objective is to evaluate adherence to a personalized, online breast cancer prevention program focused on lifestyle and its acceptance among women at high or very high risk of developing cancer who participated in the MyPeBS study.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Intervention — Virual Webinar and online personalised clinical visit

Primary Outcomes

  • Acceptance (From start of the inclusion up to the end of inclusions)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-19
Completion: 2027-06
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 1508 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNICANCER
Collaborators: European Union
Contact Information
Study Contact:
Pauline VIDICAN, MD
04 72 11 30 09
pauline.vidican@gmail.com
Centre Médical et Dentaire de Lyon MGEN
Suzette DELALOGE, MD
(+33) 1 42 11 42 11
Suzette.Delaloge@gustaveroussy.fr
Gustave Roussy
Livia Giordano, MD
+38 0116333852
livia.giordano@cpo.it
AOU Città della Salute e della Scienza - CPO PiedmontSSD Epidemiologia e Screening
Interventions
  • Behavioral: Intervention — Virual Webinar and online personalised clinical visit
Study Locations (3 sites)
Centre Médical et Dentaire de Lyon MGEN, Lyon, 69003 France
Gustave Roussy, Villejuif, France
AOU Città della Salute e della Scienza - CPO PiedmontSSD Epidemiologia e Screening, Torino, Italy
Eligibility Criteria
Inclusion Criteria: 1. Female (whether born female or not) 2. Women aged 40 to 74 years (inclusive) 3. Women who have participated in, or are participating in the MyPeBS study and who fulfilled all the inclusion and non-inclusion criteria for the MyPeBS study. 4. Women able to express their non-opposition to participate in the intervention 5. Women who were assessed as being at high (≥≥1.67% - 5.9%) or very high (≥≥6%) risk of invasive breast cancer at 5 years in the MyPeBS study Exclusion Criteria: 1\. Women who developed a breast cancer during their follow-up in the MyPeBS study
Conditions Breast Cancer, Peripheral Neuropathy
Phase PHASE2
Enrollment 116
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a double-blinded randomized controlled clinical trial that aims to study if desloratadine can reduce rates of peripheral neuropathy development in patients with breast cancer receiving taxane chemotherapy. Researchers will compare desloratadine to a placebo (look-alike substance with no drug) and use validated neurotoxicity and quality of life questionnaires to determine if desloratadine can be used to prevent or make taxane induced peripheral neuropathy (TPIN) symptoms better.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Triple

Interventions / Regimen

  • Drug: Desloratodine — Desloratadine 5mg PO every other day for 12 weeks. Desloratadine is a long- acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Desloratadine inhibited histamine release from human mast cells.
  • Drug: Placebo — Placebo daily PO for 12 weeks. Placebo is a lactose filler covered by a capsule.

Primary Outcomes

  • Change in Functional Assessment of Cancer Therapy (FACT)/Gynecologic Oncology Group (GOG)-Neurotoxicity (NTX) Subscale Version 4 (FACT-GOG-NTX) neuropathy score (From baseline to after completion of 12 weeks of taxane chemotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-09
Completion: 2030-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 116 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Montefiore Medical Center
Principal Investigators:
  • Jesus R Anampa, MD, MS (PRINCIPAL_INVESTIGATOR) - Montefiore Medical Center
Contact Information
Study Contact:
Jesus R Anampa, MD, MS
7184058505
janampa@montefiore.org
Rikin Ghandi
9149531890
rikin.gandhi@einsteinmed.edu
Jesus Anampa, MD, MS
718-405-8505
janampa@montefiore.org
Montefiore Medical Center
Interventions
  • Drug: Desloratodine — Desloratadine 5mg PO every other day for 12 weeks. Desloratadine is a long- acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Desloratadine inhibited histamine release from human mast cells.
  • Drug: Placebo — Placebo daily PO for 12 weeks. Placebo is a lactose filler covered by a capsule.
Study Locations (1 sites)
Montefiore Medical Center, The Bronx, New York 10467 United States
Eligibility Criteria
Inclusion Criteria: * Patients must have histologically confirmed breast cancer, stage I-III as per the American Joint Committee on Cancer (AJCC) 8th edition (Anatomic Staging) * Patients must be planned to receive taxane-based regimen for breast cancer (Adjuvant or neoadjuvant) of at least 12 weeks duration. Patients planned to receive taxanes in combination with other chemotherapy drugs (including platinums) are eligible. Patients planned to receive taxanes plus single or dual antiher2 therapy are also eligible. Patients planned to receive taxane-based regimen with immune checkpoint inhibitors are also allowed * Age ≥18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%) * Patients must have an adequate organ and marrow function as defined below: * absolute neutrophil count ≥1,000/microliter (mcL) * platelets ≥100,000/mcL * total bilirubin ≤ institutional upper limit of normal (ULN) * AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN * Creatinine ≤ institutional ULN * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients with prior diagnosis of diabetes mellitus are allowed if the patient has no peripheral neuropathy * Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants * Patients must not have received prior taxane or platinum therapy * Women of childbearing potential must have a negative pregnancy test: serum or urine beta human chorionic gonadotropin (hCG) within 14 days prior to first dose of study treatment * Potential fertile subjects must agree to use adequate contraception (double barrier methods of birth control or abstinence) prior to start of treatment, for the duration of treatment, and 28 days after last study medication dose. If male, must also agree to refrain from donating sperm during this period Exclusion Criteria: * Patients with prior diagnosis of peripheral neuropathy * Patients who received chemotherapy for the current breast cancer diagnosis before the planned taxane-based regimen * Patients who are receiving any other investigation agents * Patients with concurrent use of antihistamines during or for 2 days prior to the study period * History of allergic reactions attributed to compounds of similar chemical or biologic composition to desloratadine * Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous * Pregnant or breastfeeding women are not allowed in the study * Patients who are taking probiotics * Patients who are using chronic laxatives or enema * Patients who used antibiotics within 4 weeks of registration
Conditions Asthma
Phase NA
Enrollment 26
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To determine the additional effects of scalene hold relax technique with conventional exercises on pulmonary function in asthma patients

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Scalene Hold Relax Technique — Scalene Hold Relax Technique Scalene Hold for 10 Second 10 Repetition. Hold your arms behind your back to keep them from rising then slowly tilt your head trying to touch your ear to your shoulder. Bend your neck only as far as it is comfortable, and hold for 5 to 10 seconds. Relax your neck and repeat 2-3 times on each side. The treatment will be provided for 1-4 weeks as per need
  • Other: Conventional Physical Therapy — Diaphragmatic Breathing Exercise Inhale through nose about 4 Seconds, hold Breath for 2 Seconds, repeat 5 times, exercise repeated for 2-3 days per week followed up to 4 weeks. \+ Buteyko Breathing Exercise Exhale slowly and then hold that breath. Use index figure and thumb to plug nose hold that breath until there is an urge to breathe and then inhale Breathe normally at least 10 second repeat several. Frequency 2-3 days per week with Moderate Intensity follow-up to 4weeks

Primary Outcomes

  • Asthma Control Questionnaire (4 week)
  • Asthma Control Test (4 week)
  • Lara Asthma Symptoms Scale (4 week)
  • FEV1 (4 week)
  • FVC (4 week)
  • PEF (4 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-21
Completion: 2025-10
Eligibility
Age: 22 Years and older
Sex: ALL
Volunteers: true
Enrollment: 26 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Riphah International University
Principal Investigators:
  • Muhammad Iqbal Tariq, PhD* (PRINCIPAL_INVESTIGATOR) - Riphah International University
Contact Information
Study Contact:
Muhammad Iqbal Tariq, PhD*
+923338236752
iqbal.tariq@riphah.edu.pk
Ayesha Sabir, MSPT*
+92317 8099120
ayeshasabir536@gmail.com
DHQ Hospital
Ayesha Sabir, MSPT*
DHQ Hospital
Interventions
  • Other: Scalene Hold Relax Technique — Scalene Hold Relax Technique Scalene Hold for 10 Second 10 Repetition. Hold your arms behind your back to keep them from rising then slowly tilt your head trying to touch your ear to your shoulder. Bend your neck only as far as it is comfortable, and hold for 5 to 10 seconds. Relax your neck and repeat 2-3 times on each side. The treatment will be provided for 1-4 weeks as per need
  • Other: Conventional Physical Therapy — Diaphragmatic Breathing Exercise Inhale through nose about 4 Seconds, hold Breath for 2 Seconds, repeat 5 times, exercise repeated for 2-3 days per week followed up to 4 weeks. \+ Buteyko Breathing Exercise Exhale slowly and then hold that breath. Use index figure and thumb to plug nose hold that breath until there is an urge to breathe and then inhale Breathe normally at least 10 second repeat several. Frequency 2-3 days per week with Moderate Intensity follow-up to 4weeks
Study Locations (1 sites)
DHQ Hospital, Mānsehra, Khyber PkahtoonKhwa 21300 Pakistan
Eligibility Criteria
Inclusion Criteria: * Patient diagnosed with Allergic asthma * Both male and female will be included * Age between 20 to 44 years. Exclusion Criteria: * Patient who do not provide consent * Patient with any comorbid condition such as cardiovascular disease diabetes or other chronic illness * Patient with any psychological condition that may interfere with participation or adherence to the study protocol
Conditions Depression, Psychiatric Diagnosis, Perso...
Phase Not Applicable
Enrollment 415
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The project investigates long-term prognosis and predictors of treatment outcomes for difficult-to-treat depression in patients in secondary psychiatric care. The current patient cohort was collected in 2012-2021 in the study "Pharmacogenetics in patients with depression with specific focus on difficult-to-treat depression, suicide attempt and CYP2D6". The cohort consists of 415 patients, examined carefully regarding diagnostic assessment and earlier treatment. All participants were also genotyped for the drug metabolizing enzymes CYP2D6 and CYP2C19. Blood samples were stored in biobank for other analyses linked to prognostic markers. The patient cohort will now be followed up with a review of medical records and extraction of register data for a period of 5 years after their participation in the original study. The purpose of the study is to improve treatment and increase knowledge about long-term prognosis in difficult-to-treat depression. This is done by examining symptom profiles, monitoring clinical course and suicidality, and examining prognostic markers.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention is used. — No intervention is used.

Primary Outcomes

  • Suicide attempt and suicide (5 years follow-up after baseline visit.)
  • Clinical course of depression (5 years follow-up after baseline visit)
  • Comparison of diagnostic assessment for personality disorders (Baseline data and 5 years follow-up from inclusion.)
  • Course and diagnostic characteristics of bipolar disorder (Baseline data and 5 years follow-up after inclusion.)
  • Results from pharmacological counseling for CYP2D6UM och CYP2D6PM (Nine weeks of pharmacological counseling after baseline and 5 years follow-up from baseline visit)
  • Prediction of long-term prognosis of depressive symptom profiles (5 years follow-up from baseline visit)
  • Course of disease related to dopamine D3 receptor and other biomarkers (5 years follow-up from baseline visit)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 415 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Region Skane
Collaborators: Lund University
Contact Information
Study Contact:
Marie Asp, MD, PhD
+46702731013
marie.asp@skane.se
Marie Asp, PhD
+46702731013
marie.asp@med.lu.se
Research Unit, Office of Psychiatricy, habilitation and technical aid
Interventions
  • Other: No intervention is used. — No intervention is used.
Study Locations (2 sites)
Psychiatry Reserach Unit, Lund, 221 85 Sweden
Research Unit, Office of Psychiatricy, habilitation and technical aid, Lund, 221 85 Sweden
Eligibility Criteria
Inclusion Criteria: Participation in the study "Pharmacogenetics in depressive patients with specific focus on difficult-to-treat depression, suicide attempt and CYP2D6" Exclusion Criteria: Not wanting to participate in the follow-up study